Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Healthcare Associated Infections II: Preventive Measures01:22

Healthcare Associated Infections II: Preventive Measures

4.1K
Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
4.1K
Endocarditis II: Clinical Features of Infective Endocarditis01:25

Endocarditis II: Clinical Features of Infective Endocarditis

535
Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...
535
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

11.0K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K
Complement System01:27

Complement System

10.8K
The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a...
10.8K
Complementation Tests00:49

Complementation Tests

6.3K
A complementation test is a simple cross to identify whether the two mutations are located on the same gene or different genes. It was first performed by Edward Lewis in the 1940s while working on fruit flies. He developed the test to identify the location and arrangement of different mutations on chromosomes.
Organisms heterozygous for different mutations are crossed pairwise in all combinations. If present on different genes, the mutations can complement each other by providing the missing...
6.3K
Design Consideration01:22

Design Consideration

582
Designing a structure involves a series of considerations, primarily the material's ultimate strength, calculated through tests that measure changes under increased force until the material reaches its breaking point or limit. The ultimate load, where the material breaks, is divided by its original cross-sectional area, resulting in the ultimate normal stress or strength. The ultimate shearing stress is another significant factor taken into account.
The factor of safety is another key...
582

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pegcetacoplan for Adolescents with C3 Glomerulopathy or Primary Immune Complex Membranoproliferative GN: Phase 3 VALIANT Subgroup Analysis.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same author

Comparing Efficacy and Safety of Itraconazole Solution Versus Posaconazole for Antifungal Prophylaxis After Heart Transplant.

Open forum infectious diseases·2026
Same author

A nephritic puzzle: C3-dominant glomerulonephritis as a sentinel of hidden autoinflammatory disease.

Pediatric nephrology (Berlin, Germany)·2026
Same author

Strategies to Mitigate Infection Risk in Patients Receiving Complement Inhibitor Therapy.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Proteinuria Trajectory and Disease Progression in Children and Adults with IgA Nephropathy/Vasculitis.

Clinical journal of the American Society of Nephrology : CJASN·2025
Same author

Post-transplant Thrombotic Microangiopathy.

Journal of the American Society of Nephrology : JASN·2025
Same journal

A Patient's Perspective on Arteriovenous Fistula Care and Far-Infrared Radiation Arteriovenous Fistula Therapy.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same journal

A Beacon of Hope: Pegcetacoplan for Adolescents with C3 Glomerulopathy or Primary Immune Complex Membranoproliferative GN.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same journal

Sequential Biomarker Testing in Kidney Transplant Surveillance: How Far Does One Step at a Time Take Us?

Clinical journal of the American Society of Nephrology : CJASN·2026
Same journal

The Predicting Risk of Cardiovascular Disease Event Equation Meets CKD.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same journal

Muscle Cramp Rate, Severity and Burden in Maintenance Hemodialysis Patients: A Yearlong Multicenter Quality Improvement Initiative.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same journal

From Risk Determinants to Clinical Action: Understanding and Implementing the Cardiovascular Kidney Metabolic Syndrome Framework.

Clinical journal of the American Society of Nephrology : CJASN·2026
See all related articles

Related Experiment Video

Updated: Feb 8, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.7K

Practical Considerations for Infection Prevention with the Clinical Use of Complement Inhibitors.

Anuja Java1, Aruna Subramanian2, Carla Nester3

  • 1Division of Nephrology, Washington University School of Medicine, St. Louis, Missouri.

Clinical Journal of the American Society of Nephrology : CJASN
|February 6, 2026
PubMed
Summary
This summary is machine-generated.

Complement inhibitors treat kidney diseases but raise infection risks. Healthcare providers must implement preventive measures against serious infections like Neisseria meningitidis.

Keywords:
IgA nephropathycomplementgenetic kidney diseaseglomerular diseasesprimary GN

More Related Videos

PRP as a New Approach to Prevent Infection: Preparation and In vitro Antimicrobial Properties of PRP
06:36

PRP as a New Approach to Prevent Infection: Preparation and In vitro Antimicrobial Properties of PRP

Published on: April 9, 2013

22.1K
Practical Considerations in Studying Metastatic Lung Colonization in Osteosarcoma Using the Pulmonary Metastasis Assay
07:44

Practical Considerations in Studying Metastatic Lung Colonization in Osteosarcoma Using the Pulmonary Metastasis Assay

Published on: March 12, 2018

10.7K

Related Experiment Videos

Last Updated: Feb 8, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.7K
PRP as a New Approach to Prevent Infection: Preparation and In vitro Antimicrobial Properties of PRP
06:36

PRP as a New Approach to Prevent Infection: Preparation and In vitro Antimicrobial Properties of PRP

Published on: April 9, 2013

22.1K
Practical Considerations in Studying Metastatic Lung Colonization in Osteosarcoma Using the Pulmonary Metastasis Assay
07:44

Practical Considerations in Studying Metastatic Lung Colonization in Osteosarcoma Using the Pulmonary Metastasis Assay

Published on: March 12, 2018

10.7K

Area of Science:

  • Nephrology
  • Immunology
  • Pharmacology

Background:

  • Complement system overactivation is implicated in severe kidney diseases.
  • Targeting the complement system with inhibitors is a key research area for improving patient outcomes.
  • Approved complement inhibitors include eculizumab, ravulizumab, avacopan, iptacopan, and pegcetacoplan.

Purpose of the Study:

  • To review infectious risks associated with complement inhibitors used in kidney disease treatment.
  • To highlight clinical considerations for the safe and effective use of these therapies.

Main Methods:

  • Literature review of complement inhibitors and associated infections.
  • Analysis of FDA-approved complement inhibitors for kidney diseases.
  • Summary of clinical guidance for managing infectious risks.

Main Results:

  • Complement inhibitors, while effective, increase the risk of serious infections.
  • Encapsulated organisms (Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae type b) are primary concerns.
  • Prophylactic measures are crucial for patients on complement inhibitor therapy.

Conclusions:

  • Healthcare providers must be aware of and mitigate the infectious risks of complement inhibitors.
  • Safe and effective use of complement inhibitors requires vigilant monitoring and preventive strategies.
  • This review serves as a resource for clinicians managing patients on complement inhibitors for kidney diseases.